Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534179 | 1.00 | KDM4E (0.30) | KDM4ESLC7A5 | |
| SCHEMBL10321648 | 0.87 | FGFR4 (0.34) | SLC7A5 | |
| SCHEMBL11024456 | 0.81 | GRM5 (0.35) | SLC7A5 | |
| SCHEMBL533335 | 0.78 | SLC7A5 (0.34) | SLC7A5 | |
| SCHEMBL533686 | 0.77 | SLC7A5 (0.36) | SLC7A5 | |
| SCHEMBL534122 | 0.77 | GSTO1 (0.34) | KDM4E | |
| SCHEMBL534121 | 0.77 | GSTO1 (0.34) | KDM4E | |
| SCHEMBL10316777 | 0.76 | KDM4E (0.32) | KDM4E | |
| SCHEMBL10316776 | 0.76 | KDM4E (0.32) | KDM4E | |
| SCHEMBL10322535 | 0.75 | CYP1A2 (0.49) | KDM4ESLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| US-20120184747-A1 | ANILINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184747-A1 | ANILINE COMPOUND | PTGER2, ADRB2, PTGER1 | KDM4E 3983/4885SLC7A5 2361/4885 |
| US-20120226036-A1 | SUBSTITUTED CARBONYL COMPOUND | PTGER2, PTGER1, LTB4R2 | KDM4E 3416/4885SLC7A5 3613/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | KDM4E 3706/4885SLC7A5 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.